Table 1. Event outcomes: Number of events (event rate)a

BP GoalDrug Groupb
LowUsualRamiprilAmlodipineMetoprolol
a Scr, serum creatinine; iGFR, iothalamate GFR; eGFR, estimated GFR.
b Event summaries for the three drug groups include events through termination of the amlodipine arm in September 2000 only.
c Includes 379 (0.090) events (overall event rate), including 246 for 50% reductions in iGFR, 63 additional events for ESRD where the patient had not had a recorded 50% reduction in GFR, and 70 additional deaths before either a 50% reduction in iGFR or ESRD.
d Includes 302 (0.068) total events (overall event rate), including 136 for 50% reductions in Scr, 88 additional events for ESRD, and 78 additional deaths.
e Includes 309 (0.074) total events (overall event rate), including 246 50% reductions in iGFR and 63 additional events for ESRD.
f Includes 224 (0.051) total events (overall event rate), including 136 50% reductions in Scr and 88 additional events for ESRD.
50% reduction in GFR, ESRD, or deathc (G1)196 (0.096)183 (0.085)104 (0.071)62 (0.088)136 (0.096)
Doubling of Scr, ESRD, or deathd (S1)147 (0.067)155 (0.069)79 (0.052)51 (0.069)96 (0.064)
50% reduction in GFR or ESRDe (G1)164 (0.080)145 (0.067)87 (0.060)50 (0.071)111 (0.078)
Doubling of Scr or ESRDf (S1)110 (0.050)114 (0.051)60 (0.040)38 (0.052)67 (0.044)